secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001104659-24-005595
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode raises $7.25M in public offering; expects to regain Nasdaq equity compliance
--------------------------------------------------------------------------------

- Priced public offering of 5,942,623 shares (or pre-funded warrants) and warrants for 11,885,246 shares at $1.22/unit.
- Gross proceeds of $7.25M; net proceeds for clinical trials of TTX-MC138 and working capital.
- Offering closed Jan 22, 2024; warrants exercisable at $1.22, expire in 3.5 years.
- Company believes stockholders' equity now above $2.5M; Nasdaq compliance plan submitted and under review.
- H.C. Wainwright acted as placement agent; received agent warrants for 356,557 shares at $1.525.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/0001104659-24-005595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924005595/tm243790d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-005595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer